- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Roche, Janssen Expand Partnership
New agreement expands companion diagnostics to build on personalized healthcare commitment.
Roche is expanding its collaboration with Janssen Biotech to create companion diagnostics for targeted therapies and further strengthen research and innovation activities.
As per the agreement, Roche and Janssen will look to collaborate in the precision medicine field with multiple companion diagnostics technologies, including immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction and immunoassays. Potential products include exploring data and tissue image analysis and the development of a new IHC assay to support patient identification and enrollment for personalized treatment.
“Through collaboration, we aim to help advance personalized healthcare by developing tests that make more targeted therapies available to the patients who need them,” says Jill German, head of pathology lab at Roche Diagnostics.
Diagnostic Tool That Identifies Patients Suitable for Keytruda Treatment Gets Latest FDA Approval
November 14th 2023PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.
